We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

III:LSE3i Group plc Analysis

Data as of 2026-03-10 - not real-time

£2,927.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

3i Group (III.L) trades at a PE ratio of 4.5, far below the industry average of 17.4, and the DCF model suggests a fair value around £15,163, implying roughly a 43% upside from the current price. The company delivers exceptional profitability with an operating margin of 97.8% and a net profit margin of 94.8%, while generating strong free cash flow of £4.08 bn, supporting its 2.7% dividend yield and a modest payout ratio of 11%. However, leverage is elevated, reflected by a debt‑to‑equity ratio above 4, and the price‑to‑book metric appears inflated, indicating potential balance‑sheet risk. Technical indicators show the stock is oversold (RSI ~35) and sitting just above a key support level of £28.97, but it remains below the 20‑day SMA and the MACD is bearish, suggesting short‑term pressure.
The high 30‑day volatility (≈48%) combined with a low beta (≈0.58) points to price swings that are not strongly correlated with the broader market, while the asset‑management sector carries moderate regulatory and geographic exposure. Given the substantial valuation gap, robust cash generation, and sustainable dividend, the stock is positioned as an attractive long‑run play, albeit with caution around its leverage and short‑term technical weakness.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI indicating potential bounce
  • Proximity to strong support level
  • Significant DCF upside potential

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Exceptionally low PE relative to peers
  • High free cash flow supporting dividend and reinvestment
  • Strong earnings growth and margin profile

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Elevated debt‑to‑equity ratio raising balance‑sheet risk
  • Sustained dividend yield with low payout ratio
  • Fundamental undervaluation despite sector volatility

Key Metrics & Analysis

Financial Health

Revenue Growth72.10%
Profit Margin94.82%
P/E Ratio4.5
ROE25.05%
ROA15.27%
Debt/Equity4.45
P/B Ratio102.3
Op. Cash Flow£830.0M
Free Cash Flow£4.1B
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI35.1
Support£2,896.70
Resistance£3,564.00
MA 20£3,268.00
MA 50£3,251.64
MA 200£3,779.35
MACDBearish
VolumeStable
Fear & Greed Index79.18

Valuation

Fair Value£15,163.40
Target Price£4,200.50
Upside/Downside43.51%
GradeUndervalued
TypeBlend
Dividend Yield2.70%

Risk Assessment

Beta0.58
Volatility47.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.